Grimes & Company, Inc. Heron Therapeutics, Inc. Transaction History
Grimes & Company, Inc.
- $3.66 Billion
- Q3 2024
A detailed history of Grimes & Company, Inc. transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 47,863 shares of HRTX stock, worth $85,196. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,863
Previous 47,863
-0.0%
Holding current value
$85,196
Previous $167,000
43.11%
% of portfolio
0.0%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding HRTX
# of Institutions
190Shares Held
129MCall Options Held
94.7KPut Options Held
148K-
Rubric Capital Management LP New York, NY26.7MShares$47.6 Million2.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.62MShares$15.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.33MShares$14.8 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA7.6MShares$13.5 Million0.05% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$12.4 Million58.47% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $211M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...